Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Telomerase is a ribonucleoprotein complex that elongates telomeric DNA and appears to play an important role in cellular immortalization of cancers. Because telomerase is expressed in the vast majority of malignant gliomas but not in normal brain tissues, it is a logical target for gliomaspecific therapy. The telomerase inhibitor GRN163, a 13-mer oligonucleotide N3'-->P5' thio-phosphoramidate (Geron Corporation, Menlo Park, Calif.), is complementary to the template region of the human telomerase RNA subunit hTR. When athymic mice bearing U-251 MG human brain tumor xenografts in their flanks were treated intratumorally with GRN163, a significant growth delay in tumor size was observed (P < 0.01 in all groups) as compared to the tumor size in mice receiving a mismatched oligonucleotide or the carrier alone. We also investigated biodistribution of the drug in vivo in an intracerebral rat brain-tumor model. Fluorescein-labeled GRN163 was loaded into an osmotic minipump and infused directly into U-251 MG brain tumors over 7 days. Examination of the brains revealed that GRN163 was present in tumor cells at all time points studied. When GRN163 was infused into intracerebral U-251 MG tumors shortly after their implantation, it prevented their establishment and growth. Lastly, when rats with larger intracerebral tumors were treated with the inhibitor, GRN163 increased animal survival times. Our results demonstrate that the antitelomerase agent GRN163 inhibits growth of glioblastoma in vivo, exhibits favorable intracerebral tumor uptake properties, and prevents the growth of intracerebral tumors. These findings support further development of this compound as a potential anticancer agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GRN163L effectively inhibits telomerase activity of various human cancer cell lines67-70, resulting in progressive telomere shortening and induction of cellular senescence to suppress tumor cell growth in vitro.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [70]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2×
“The CHAPS extracts with equivalent protein concentrations were prepared and evaluated with the telomeric repeat amplification protocol assay to measure telomerase activity (Kim et al., 1994).”
BackgroundMethodNonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
Identification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 1×
“Telomerase is a specialized ribonucleoprotein polymerase that contains the integral RNA component hTR with a short template segment that directs the synthesis of telomeric repeats at the ends of chromosomes (Greider and Blackburn, 1985; Yu et al., 1990).”
BackgroundCounter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096 · cited 1×
“Thus, cancer cell DNA is continuously extended or maintained by telomerase to compensate for the loss of telomeric repeats (Counter et al., 1992), and as a result the cells become immortalized.”
BackgroundSurgical Pathology of the Nervous System and its Coverings
Blumbergs, P. C. (2003) · Pathology · doi:10.1016/s0031-3025(16)39703-3 · Cited by 918
Yu, G.-L., Bradley, J. D., Attardi, L. D., & Blackburn, E. H. (1990) · Nature · doi:10.1038/344126a0 · Cited by 632 · cited 1×
“Telomerase is a specialized ribonucleoprotein polymerase that contains the integral RNA component hTR with a short template segment that directs the synthesis of telomeric repeats at the ends of chromosomes (Greider and Blackburn, 1985; Yu et al., 1990).”
BackgroundCorrelating telomerase activity levels with human neuroblastoma outcomes
Hiyama, E., Hiyama, K., Yokoyama, T., Matsuura, Y., Piatyszek, M. A., & Shay, J. W. (1995) · Nature Medicine · doi:10.1038/nm0395-249 · Cited by 611 · cited 1×
“In contrast, telomerase is expressed and functionally active in a wide variety of human tumors, including bladder, breast, prostate, and head and neck tumors (Hiyama et al., 1995; Kim et al., 1994; Lin et al., 1996; Mao et al., 1996; Sommerfeld et al., 1996; Sugino et al., 1996).”
BackgroundLevin, V. A., Silver, P., Hannigan, J., Wara, W. M., Gutin, P. H., Davis, R. L., & Wilson, C. B. (1990) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(90)90096-3 · Cited by 401 · cited 2×
“…by the Society for Neuro-Oncology by guest on Septem ber 14, 2016 http://neuro-oncology.oxfordjournals.org/ D ow nloaded from Neuro-Oncology JULY 2004 219 Patients with these tumors typically undergo surgery followed by radiation therapy and chemotherapy (Levin et al., 1990; Recht et al., 1990).”
BackgroundTelomerase activity: a prevalent marker of malignant human prostate tissue.
Sommerfeld, H. J., Meeker, A. K., Piatyszek, M. A., Bova, G. S., Shay, J. W., & Coffey, D. S. (1996) · PubMed · Cited by 391
Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme
Hakin-Smith, V, Jellinek, D., Levy, D., Carroll, T., Teo, M., Timperley, W., McKay, M., Reddel, R., & Royds, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12681-5 · Cited by 267 · cited 1×
“It is important to note that a group of gliomas with exceptionally long telomeres, 17 kb, have been identified (Hakin-Smith et al., 2003).”
Background
Research works printed but not linked: 1
- Yu, G.L., Bradley, J.D., Attardi, M.L., and Blackburn, E.H. (1990) In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature344,126 -132. · DOI · Paper page
Cited by
Telomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Telomere dysfunction and tumour suppression: the senescence connection
Deng, Y., Chan, S. S., & Chang, S. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2393 · Cited by 411
In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271
“The oligonucleotide sequence 5VTAGGGTTAGACAA-3V is complementary to a 13-nucleotide-long region partially overlapping and extending by four nucleotides beyond the 5Vboundary of the template region of hTR (39).”
BackgroundSelf-citationHerbert, B.-S., Gellert, G. C., Hochreiter, A., Pongracz, K., Wright, W. E., Zielinska, D., Chin, A. C., Harley, C. B., Shay, J. W., & Gryaznov, S. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208760 · Cited by 268
“Other types of modified ionic oligonucleotides with a 30-bridging nitrogen, such as N30-P50 phosphoramidate and thio-phosphoramidates, have already been shown to be potent telomerase inhibitors (Herbert et al., 2002; Akiyama et al., 2003; Asai et al., 2003; Ozawa et al., 2004; Wang et al., 2004).”
BackgroundResultSelf-citation
Metadata
- Authors
- Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R., & Deen, D. F.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Ozawa, Tomoko
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 6
- Issue
- 3
- Pages
- 218-226
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC1871998
- OpenAlex
- W2126407488
- Cited by
- 56
- References
- 30
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 5 · 2020: 1 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1 · 2013: 3 · 2012: 4
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of California, San Francisco
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA and Nucleic Acid Chemistry
- Keywords
- telomerase inhibitors, glioblastoma, antisense oligonucleotides, tissue distribution, tumor growth inhibition, survival, brain tumor therapy
- MeSH terms
- Animals, Antineoplastic Agents, Brain Neoplasms, Enzyme Inhibitors, Female, Glioblastoma, Humans, Male, Mice, Inbred BALB C, Mice, Nude, Oligonucleotides, Rats, Nude, Telomerase, Xenograft Model Antitumor Assays, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. https://app.cochat.ai/papers/10.1215/s1152851704000055
- The paper
- Ozawa, T., Gryaznov, S. M., Hu, L. J., Pongracz, K., Santos, R. A., Bollen, A. W., Lamborn, K. R., & Deen, D. F. (2004). Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. Neuro-Oncology. https://doi.org/10.1215/s1152851704000055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.